Altered uric acid levels and disease states

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 1-7

  Kutzing, Melinda K ^a   Firestein, Bonnie L ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; DISEASE MARKER; GOUT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; GOUT; HUMANS; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; KIDNEY DISEASES; NEURONS; PEROXYNITROUS ACID; URIC ACID;

EID: 37349088959     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.129031     Document Type: Review

References (69)

1. Alper AB, Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, and Hamm LL (2005) Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 45:34-38.
2. Ames BN, Cathcart R, Schwiers E, and Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78:6858-6862.
3. Anzai N, Kanai Y, and Endou H (2007) New insights into renal transport of urate. Curr Opin Rheumatol 19:151-157.
4. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, and Koprowski H (1995) Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 92:12041-12045.
5. Beckman JS (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836-844.
6. Berger L and Yu TF (1975) Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 59:605-613.
7. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, and Breteler MM (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37:1503-1507.
8. Choi HK, Mount DB, and Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143:499-516.
9. Church WH and Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 33:419-425.
10. Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235:747-754.
11. de Lau LM, Koudstaal PJ, Hofman A, and BretelerMM(2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797-800.
12. De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, and Serruys PW (1991) Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 68:392-395.
13. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D, Peric V, Dragutinovic G, Marinkovic J, Levic Z, et al. (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248:121-126.
14. Du Y, Chen CP, Tseng CY, Eisenberg Y, and Firestein BL (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463-472.
15. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, and Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80:101-110.
16. Emmerson BT (1996) The management of gout. N Engl J Med 334:445-451.
17. Fang J and Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404-2410.
18. Ferguson B, Matyszak MK, Esiri MM, and Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
19. Freedman DS, Williamson DF, Gunter EW, and Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637-644.
20. Friedl HP, Till GO, Trentz O, and Ward PA (1991) Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients. Klin Wochenschr 69:1109-1112.
21. Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, and Poderoso JJ (2000) Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 4:534-539.
22. Hediger MA, Johnson RJ, Miyazaki H, and Endou H (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20:125-133.
23. Hisatome I, Tsuboi M, and Shigemasa C (1996) [Renal hypouricemia]. Nippon Rinsho 54:3337-3342.
24. Hooper DC, Ohnishi ST, Kean R, Numagami Y, Dietzschold B, and Koprowski H (1995) Local nitric oxide production in viral and autoimmune diseases of the central nervous system. Proc Natl Acad Sci U S A 92:5312-5316.
25. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, and Spitsin SV (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14:691-698.
26. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, and Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95:675-680.
27. Inoue S and Kawanishi S (1995) Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett 371:86-88.
28. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, and Beckman JS (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298:431-437.
29. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl. 3):S26-S36.
30. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, and Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183-1190.
31. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, and Trevisan M (1994) Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 8:677-681.
32. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, and Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897.
33. Kang DH, Park SK, Lee IK, and Johnson RJ (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16:3553-3562.
34. Kean RB, Spitsin SV, Mikheeva T, Scott GS, and Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165:6511-6518.
35. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, and Lee CU (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21:344-348.
36. Klemp P, Stansfield SA, Castle B, and Robertson MC (1997) Gout is on the increase in New Zealand. Ann Rheum Dis 56:22-26.
37. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, and Gottlob I (2004) Serum uric acid levels in optic neuritis. Mult Scler 10:278-280.
38. Lee J, Sparrow D, Vokonas PS, Landsberg L, and Weiss ST (1995) Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 142:288-294.
39. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, and Coats AJ (1998) Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19:1814-1822.
40. Lin KC, Lin HY, and Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501-1505.
41. Liu F, You SW, Yao LP, Liu HL, Jiao XY, Shi M, Zhao QB, and Ju G (2006) Secondary degeneration reduced by inosine after spinal cord injury in rats. Spinal Cord 44:421-426.
42. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, and Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106.
43. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, and Aristimuno GG (1980) Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 93:817-821.
44. Mount DB, Kwon CY, and Zandi-Nejad K (2006) Renal urate transport. Rheum Dis Clin North Am 32:313-331, vi.
45. Nieto FJ, Iribarren C, Gross MD, Comstock GW, and Cutler RG (2000) Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 148:131-139.
46. Pacher P, Beckman JS, and Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424.
47. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, and Fisher ND (2004) Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 66:1465-1470.
48. Pietraforte D, Castelli M, Metere A, Scorza G, Samoggia P, Menditto A, and Minetti M (2006) Salivary uric acid at the acidic pH of the stomach is the principal defense against nitrite-derived reactive species: sparing effects of chlorogenic acid and serum albumin. Free Radic Biol Med 41:1753-1763.
49. Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, de Miguel E, and Gijon JB (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726-732.
50. Puig JG and Ruilope LM (1999) Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 17:869-872.
51. Radi R, Beckman JS, Bush KM, and Freeman BA (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:481-487.
52. Radi R, Rodriguez M, Castro L, and Telleri R (1994) Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 308:89-95.
53. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, and Vassilopoulos D (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108:527-531.
54. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, and Kato E (1978) Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 26:241-247.
55. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, and Herrera-Acosta J (2002) Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283:F1105-F1110.
56. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, and Hooper DC (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 102:3483-3488.
57. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, and Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99:16303-16308.
58. Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, and Bogdanovi (2000) nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol 165:12-26.
59. Smith KJ, Kapoor R, and Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92.
60. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, and Koprowskil H (2001a) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7:313-319.
61. Spitsin S, Hooper DC, Mikheeva T, and Koprowski H (2001b) Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins. Mult Scler 7:165-166.
62. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, and Pryor WA (2000) Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376:333-337.
63. Thorns V, Hansen L, and Masliah E (1998) nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp Neurol 150:14-20.
64. Toncev G, Milicic B, Toncev S, and Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221-226.
65. Torun M, Yardim S, Simsek B, and Burgaz S (1998) Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther 23:25-29.
66. van der Veen RC, Hinton DR, Incardonna F, and Hofman FM (1997) Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77:1-7.
67. Waring WS, Webb DJ, and Maxwell SR (2000a) Uric acid as a risk factor for cardiovascular disease. Q J Med 93:707-713.
68. Waring WS, Webb DJ, and Maxwell SRJ (2000b) Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 49:511.
69. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, and Johnson RJ (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355-360.